A147 COMBINING INFLIXIMAB TROUGH LEVELS AND FECAL CALPROTECTIN LEVELS WITH CLINICAL DATA HAS THE POTENTIAL TO GUIDE CLINICAL DECISION-MAKING IN IMPROVING OUTCOMES FOR INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE INFLIXIMAB.

BACKGROUND: Infliximab (IFX) induces and maintains remission in Crohn’s Disease (CD) and Ulcerative Colitis (UC). Secondary loss of response occurs in up to 45% of CD and 60% of UC patients on maintenance IFX. Studies are inconclusive on ideal IFX trough levels (ITLs) to prevent loss of response; re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Can Assoc Gastroenterol
Main Authors: Amin, A, Prosser, C, Kroeker, K I, Wang, H, Shalapay, C, Dhami, N, Fedorak, D K, Halloran, B P, Dieleman, L A, Goodman, K, Fedorak, R, Huang, V
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Poster Presentations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6507628/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.148
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados